



## Senzime adds 6 countries to the TetraGraph distribution network

**Press Release: Uppsala, April 25, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in Belgium, Netherlands, Luxemburg, Austria, Czech Republic and Slovakia.**

Senzime has entered exclusive distribution agreements for the commercialization of TetraGraph with Innomed Benelux B.V. in Belgium for the Netherlands and Luxemburg, and Intramed Handelsges.m.b.H in Austria and A. M. I. Analytical Medical Instruments s. r. o. in Slovakia and the Czech Republic. All three companies have management and sales forces with extensive experience in the Medical Device industry in their respective country with a focus on novel technology and the TetraGraph will be an important contribution to their existing portfolio. The agreement is based on a compensation scheme of "per-unit sold" basis and is in line with current industry compensation levels without guaranteed sales.

Lena Söderström, CEO Senzime, commented: *"We are continuing to establish distribution networks throughout Europe. With Innomed, Intramed and A.M.I., we have signed agreements with experienced organizations that through their vast networks will be great partners when marketing TetraGraph on their respective market."*

The TetraGraph is an innovative and user-friendly system for monitoring patients undergoing general anesthesia with muscle relaxant drugs. The system makes it possible to objectively determine the correct dose of muscle relaxants, and helps the clinician determine when the patient is sufficiently recovered to sustain spontaneous breathing. The system consists of a portable, hand-held patient monitoring unit and non-invasive disposable sensors.

Senzime has previously entered distribution agreements for TetraGraph in the UK, Ireland, Switzerland, Spain, Portugal, Australia and New Zealand, and licensing agreements in Japan. Discussions are ongoing with distributors for additional markets and additional agreements are expected during 2018.

**For further information, please contact:**

Lena Söderström, CEO of Senzime AB  
+46 708-16 39 12, [lena.soderstrom@senzime.com](mailto:lena.soderstrom@senzime.com)

Catrin Molund, Business Development Director  
+46 708-11 69 11, [catrin.molund@senzime.com](mailto:catrin.molund@senzime.com)

**TO THE EDITORS**

**About Senzime**

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. [www.senzime.com](http://www.senzime.com)

*This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on April 25, 2018.*